Esketamine in Treatment Resistant Depression: The Way to Remission

Esketamine in Treatment Resistant Depression: The Way to Remission

Major depressive disorder affects an estimate of 5% of the population with nearly 1‑third of patients failing to achieve remission with conventional pharmacological treatment. Esketamine, a novel rapid‑acting antidepressant, with a noncompetitive antagonism on N‑methyl‑D‑Aspartate receptor, have be...

Full description

Bibliographic Details
Main Authors: João Facucho-Oliveira, Daniel Esteves-Sousa, Bruno Prates, Rui Neves, Pedro Varandas
Format: Article
Language:English
Published: Sociedade Portuguesa de Psiquiatria e Saúde Mental 2021-03-01
Series:Revista Portuguesa de Psiquiatria e Saúde Mental
Subjects:
Antidepressive Agents
Depressive Disorder, Major/drug therapy
Depressive Disorder, Treatment‑Resistant/ drug therapy
Esketamine/administration & dosage
Online Access:https://www.revistapsiquiatria.pt/index.php/sppsm/article/view/174

Internet

https://www.revistapsiquiatria.pt/index.php/sppsm/article/view/174

Similar Items